Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13241715 | 0.85 | HSD17B10 (0.62) | HSD17B10VCAM1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2205749 | 0.85 | HSD17B10 (0.62) | HSD17B10VCAM1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1663175 | 0.83 | HSD17B10 (0.60) | HSD17B10VCAM1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL28291581 | 0.83 | HSD17B10 (0.60) | HSD17B10VCAM1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL8262558 | 0.83 | HSD17B10 (0.60) | HSD17B10VCAM1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2182437 | 0.83 | HSD17B10 (0.60) | HSD17B10VCAM1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL29906404 | 0.83 | HSD17B10 (0.60) | HSD17B10VCAM1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL842908 | 0.83 | HSD17B10 (0.60) | HSD17B10VCAM1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL28695929 | 0.81 | HSD17B10 (0.58) | HSD17B10VCAM1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL9192755 | 0.81 | TSHR (0.58) | HSD17B10LMNASMN1; SMN2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103140465-B | The method of synthesis 2-methoxymethyl-Isosorbide-5-Nitrae-phenylenediamine | THE PROCTER & GAMBLE CO. (US) | 2015-09-02 | — | — | CN | claimed |
| EP-2621885-B1 | METHODS OF SYNTHESIZING 2-METHOXYMETHYL-1,4-BENZENEDIAMINE | PROCTER & GAMBLE (US) | 2014-10-29 | — | — | EP | claimed |
| US-8759589-B2 | Methods of synthesizing 2-Methoxymethyl-1,4-benzenediamine | THE PROCTER & GAMBLE COMPANY (US) | 2014-06-24 | — | — | US | claimed |
| EP-2621885-A1 | METHODS OF SYNTHESIZING 2-METHOXYMETHYL-1,4-BENZENEDIAMINE | The Procter and Gamble Company (US) | 2013-08-07 | — | — | EP | claimed |
| CN-103140465-A | Methods of synthesizing 2-methoxymethyl-1,4-benzenediamine | PROCTER & GAMBLE | 2013-06-05 | — | — | CN | claimed |
| US-20120130128-A1 | Methods of Synthesizing 2-Methoxymethyl-1,4-Benzenediamine | WELLA OPERATIONS US, LLC | 2012-05-24 | — | — | US | claimed |
| WO-2012044758-A1 | METHODS OF SYNTHESIZING 2-METHOXYMETHYL-1,4-BENZENEDIAMINE | THE PROCTER & GAMBLE COMPANY (US) | 2012-04-05 | — | — | WO | claimed |
| EP-0128563-B1 | IMPROVED ANTIFOGGANT PROCESS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-04-04 | — | — | EP | claimed |
| EP-0128563-A2 | Improved antifoggant process | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-12-19 | — | — | EP | claimed |
| US-4468454-A | NEGATIVE SILVER HALIDE EMULSIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-08-28 | — | — | US | claimed |
| EP-0101089-A2 | Organic oxidants and radical traps for negative-working silver halide emulsions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-02-22 | — | — | EP | claimed |
| US-12187686-B2 | BRD4-JAK2 inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20210355088-A1 | BRD4-JAK2 INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-11-18 | — | — | US | disclosed |
| EP-2621888-B1 | METHODS OF SYNTHESIZING 2- SUBSTITUTED-1,4-BENZENEDIAMINE | NOXELL CORP (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-2858983-B1 | TNF-ALPHA MODULATING BENZIMIDAZOLES | UCB BIOPHARMA SPRL (BE) | 2018-04-18 | — | — | EP | disclosed |
| EP-0101089-A2 | Organic oxidants and radical traps for negative-working silver halide emulsions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-02-22 | — | — | EP | disclosed |
| EP-0010616-B1 | 4-NITRO-2-TRICHLOROMETHYLPHENYLSULFENAMIDES, FUNGICIDES CONTAINING THEM, THEIR PREPARATION AND USE IN COMBATING MUSHROOMS | BASF Aktiengesellschaft (DE) | 1981-04-29 | — | — | EP | disclosed |
| US-4261924-A | FUNGICIDES, BACTERICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1981-04-14 | — | — | US | disclosed |
| EP-0010616-A1 | 4-Nitro-2-trichloromethylphenylsulfenamides, fungicides containing them, their preparation and use in combating mushrooms | BASF Aktiengesellschaft (DE) | 1980-05-14 | — | — | EP | disclosed |
| US-4163020-A | FUNGICIDES, BACTERICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1979-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355088-A1 | BRD4-JAK2 INHIBITORS | BRD4, BICRA, JAK2 | HSD17B10 2500/4885VCAM1 2193/4885LMNA 4363/4885 |
| US-20120130128-A1 | Methods of Synthesizing 2-Methoxymethyl-1,4-Benzenediamine | HNMT, PNMT, BHMT2 | HSD17B10 1256/4885VCAM1 1061/4885LMNA 3147/4885 |
| US-12187686-B2 | BRD4-JAK2 inhibitors | BRD4, BICRA, JAK2 | HSD17B10 2500/4885VCAM1 2193/4885LMNA 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.